The Bombay High Court on Tuesday (15 July) refused to interfere with the order passed by an appellate board allowingÂ Natco PharmaÂ to manufacture and sell a generic copy of a patent-protected cancer drug made by German drug maker Bayer AG.
The court was hearing a plea filed by Bayer challenging a March 2013 order passed by the Intellectual Property Applellate Board (IPAB) permitting Natco Pharma to manufacture and sell a generic copy of the patented drug Nexavar.
The HC dismissed the case as it did not see a reason to interfere with the order passed by IPAB.
Natco is pleased to inform that the Bombay High Court upheld the compulsory license (CL) granted to the Company on Nexavar (sorafenib tosylate) of German drug Major Bayerâs patented kidney cancer drug, Natco Pharma said in a press release on Tuesday.
The Nexavar issue dates back to March 9, 2012, when the then Controller General of Patents issued the first-ever CL to the Company to manufacture an affordable generic version of sorafenib tosylate, the anti-cancer drug for which Bayer had obtained a patent, it added.